Cerebrolysin: What the Evidence Actually Shows

Most products in a research-peptide catalogue are single molecules: one sequence, one mass, one number on a certificate. Cerebrolysin is not. It is a preparation made from purified porcine brain proteins, and what is in the vial is a mixture of fragments rather than a defined compound. That single fact changes how the material should be documented, how its research literature should be read, and what any report about a batch can honestly claim.

This guide covers what Cerebrolysin is, what the randomised trials and systematic reviews have found — including the two Cochrane reviews that reach different-sounding verdicts — and what questions a mixture raises that a single peptide does not.

What Cerebrolysin is

Cerebrolysin belongs to an older tradition of pharmacology than the synthetic peptides that fill most of a modern catalogue. Rather than being built residue by residue on a resin, it is derived from tissue: a 2023 systematic review in Brain Sciences describes it as “a low molecular weight neuropeptide preparation obtained from purified porcine brain proteins”, and its abstract calls it “a mixture of neuropeptides derived from purified porcine brain proteins”. The Cochrane review of its use in stroke uses almost the same words — “a mixture of low-molecular-weight peptides and amino acids derived from porcine brain”.

As a medicine it is an aqueous solution of concentrate, held by EVER Neuro Pharma GmbH in Unterach, Austria. The prescribing information published by the company, which it states is based on the Austrian Summary of Product Characteristics, is indicated “For treatment of cerebrovascular disorders” and lists senile dementia of Alzheimer’s type, vascular dementia, stroke and craniocerebral trauma. The same company page states that the product “is not registered with the U.S. Food and Drug Administration (FDA)” and “is not approved for sale or distribution in the United States”. The Cochrane review notes that it is “widely used in the treatment of acute ischaemic stroke in Russia, Eastern Europe, China” and other Asian and post-Soviet countries — a geography that explains why much of its trial literature sits outside the journals a North American reader encounters first.

Two things are worth separating here. The approved medicine abroad and the lyophilized reagent sold for laboratory work are not the same article, even when the name on the label is the same. A research buyer is purchasing material for in-vitro work, with its own batch records; nothing about a foreign marketing authorisation transfers to it.

Why it is not a single research peptide

If you have read our guide to what peptides are, the usual picture is a defined chain: a sequence you can write out, a molecular weight you can calculate, and a main peak you can point at on a chromatogram. A tissue-derived preparation breaks all three assumptions at once.

This is not a criticism of the material; biologically derived preparations are a legitimate class, and several products in the research-peptide world share the problem. Our guide to the thymus peptides covers another family where extracts and defined synthetic peptides are routinely confused with one another. What it does mean is that anyone reading documentation on Cerebrolysin should know which question the document is answering.

What the stroke evidence shows

Acute ischaemic stroke is where Cerebrolysin has been studied most, and where the pooled picture is least flattering.

The Cochrane review Cerebrolysin for acute ischaemic stroke, updated by Ziganshina and colleagues in October 2023, pooled seven randomised trials with 1,773 participants. On the review’s primary outcomes:

The authors’ conclusion is that moderate-certainty evidence indicates “no beneficial effect on preventing all-cause death in acute ischaemic stroke”, and that the same grade of evidence “indicates a potential increase in non-fatal serious adverse events with Cerebrolysin use”. Two details are worth carrying into any reading of that verdict. First, the review records that “The manufacturer of Cerebrolysin supported three multicentre studies”, and its plain-language summary notes this “may have affected how those studies were designed, carried out, and reported”. Second, the 2023 update added a trial of Cortexin, a comparable preparation derived from cattle brain, contributing 272 participants — which is why the authors’ conclusion refers to peptide mixtures derived from cattle brain as well. Pooling two different animal-derived products under one verdict is defensible as a class judgement, but it is not the same as a verdict on Cerebrolysin alone.

Against that sits the most-cited individual trial. Cerebrolysin and Recovery After Stroke, published in Stroke in 2016 by Muresanu and colleagues, was a randomised, double-blind, placebo-controlled multicentre study that began treatment 24 to 72 hours after stroke onset and continued for 21 days alongside a standardised rehabilitation programme. Its primary outcome was the Action Research Arm Test at day 90, a measure of arm and hand motor function, and the trial reported superiority on that measure, with the authors also reporting that the preparation “was safe and well tolerated”. The authors described the study as exploratory and called for larger trials. A single positive exploratory trial and a pooled null result on mortality are not actually in conflict; they are measuring different things, at different levels of evidence. Our guide to reading a peptide study covers that distinction, and clinical trial phases explained covers where an exploratory trial sits.

Vascular dementia and brain injury

A separate Cochrane review, Cerebrolysin for vascular dementia, was published by Cui and colleagues in 2019 as the first update of a 2013 review. It included six randomised trials with 597 participants. Pooled cognitive scores favoured Cerebrolysin (standardised mean difference 0.36, 95% CI 0.13 to 0.58 across three studies and 420 people), as did response rates on global clinical impression scales (risk ratio 2.69, 95% CI 1.82 to 3.98). Adverse events did not differ significantly.

The authors’ own framing is the part usually dropped when this review is cited. They write that the courses of treatment “improved cognition and general function in people living with vascular dementia” — and immediately that “these data are not definitive”, that “Our analyses were limited by heterogeneity, and the included papers had high risk of bias”, and that “If there are benefits of Cerebrolysin, the effects may be too small to be clinically meaningful”. Every pooled estimate in that review is rated very low quality.

In traumatic brain injury the literature is larger but no cleaner. A 2023 systematic review and meta-analysis in Brain Sciences pooled ten studies covering 8,749 patients, including retrospective designs, and reported a mean difference of 0.422 (95% CI 0.262 to 0.581) on the Glasgow Outcome Scale favouring Cerebrolysin, while finding no significant effect on mortality or length of hospital stay. Its own Glasgow Coma Scale figures are reported inconsistently between the text and the accompanying figure, and the authors list the absence of large randomised trials and wide variation in how and when the preparation was given among their limitations. They name the CAPTAIN I and II trials, attributed to Poon and colleagues in 2019 and Muresanu and colleagues in 2020, as the randomised work in this area, with cognitive endpoints based on the Stroop and Color Trail tests.

What a report on a mixture can show

For a single peptide, our guides to reading an HPLC chromatogram and reading a mass spectrum describe a straightforward task: confirm one mass, point at one main peak, read one percentage. None of those three steps works unchanged on a mixture, so it is worth being explicit about what changes.

• Purity becomes meaningless as a single number. A percentage expresses how much of a sample is the target compound. Where there is no single target compound, the number has nothing to refer to — so a report quoting one for a multi-component preparation is answering a question that was not asked.
• Identity becomes a comparison. The practical question is whether the batch in hand produces the same profile as a reference batch or a reference standard. That requires something to compare against, and the comparison matters more than any individual peak.
• Mass spectrometry reports species, not a verdict. A spectrum from a mixture shows many masses. It can confirm that peptide material is present and consistent with a brain-derived preparation; it cannot confirm “the” mass of a product that has none.
• Batch-to-batch consistency carries the weight. With a process-defined product, the record that matters is whether successive lots look alike, and what the supplier does when one does not.
• Ask what the method separated. Before accepting any figure, ask which technique produced it, what it was compared with, and what the number is a percentage of. Our guide to spotting misrepresented research peptides covers the same habit in a simpler setting, and the COA guide covers what a certificate should contain.

What is established and what is not

Sourcing Cerebrolysin in Canada

For laboratory work, the questions that matter with this material differ a little from the single-peptide checklist:

• Know that you are buying a mixture. Treat documentation accordingly, and do not expect a purity percentage to mean what it means for a defined peptide.
• Record the batch. With a process-defined preparation, the lot number is the only reliable link between your results and the material you used.
• Keep it cold, dry and dark, and handle it as the lyophilized material it arrives as. See the peptide storage guide and what lyophilized means.
• Do not read foreign approvals onto a reagent. A marketing authorisation in Austria says nothing about a vial of research material in a Canadian laboratory.

CerebrolysinThe brain-derived preparationView product P21 (P021)A defined synthetic neuro reagentView product N-Acetyl SemaxA defined short peptideView product PinealonA defined tripeptideView product

Frequently asked questions